Cumhur GÜNDÜZ, Fethiye Ferda YILMAZ, Can BİÇMEN, Onur KARAMAN, Tülay AKARCA, Şevket DERELİ, Haluk AKIN, Zehra CENGİSİZ, Asude DURMAZ, Hasan TAŞLIDERE, Cengiz ÇAVUŞOĞLU, Mehmet Sezai TAŞBAKAN, Özgür ÇOĞULU, Meltem TAŞBAKAN

Investigation of miRNA and cytokine expressions in latent tuberculosis infection and active tuberculosis

Background/aim: In tuberculsosis (TB), miRNA has been used as a biomarker to distinguish between healthy individuals and TB patients. The aim of this study was to investigate (i) the association of the miRNA and cytokine expression levels, the course of tuberculosis infection, clinical forms and response to treatment, and (ii) the effects of genotypic features of bacteria on the course of tuberculosis and the relationship between miRNA and cytokine expressions and bacterial genotypes. Materials and methods: A total of 200 cases (100: culture positive active tuberculosis, 50: quantiferon positive latent tuberculosis infection and 50: quantiferon negative healthy controls) were included in the study. For the tuberculosis group at the time of admission and after treatment, for the latent tuberculosis infection and healthy control groups at the time of admission, miRNA and cytokine expressions were determined. Genotyping of M.tuberculosis isolates was performed by spoligotyping method. Results: While, in the comparison of miRNA expressions between the pretreatment patient group and the healthy control group, there was a statistically significant decrease in the expression of miR-454-3p, miR-15a-5p, miR-590-5p, miR-381, and miR-449a in the Pulmonary TB group, there was no significant change in miRNA expression in extrapulmonary TB patients. When the cytokine expressions of the patient group and the healthy control group were compared before treatment, the expressions of all cytokines in the patient group decreased. However, the only cytokine that showed a significantly lower expression was IL12A in PTB patients. Conclusion: There is no significant relationship between the clinical course of the disease, cytokine and miRNA expression, and the genotype of the bacteria.

PDF

___

1. Global Tuberculosis Report 2018 ISBN 978-92-4-156564-6 © World Health Organization 2018. Printed in France WHO/ CDS/TB/2018.20.
2. Çavuşoğlu C. History of tuberculosis and tuberculosis control program in Turkey. Microbiology Australia 2014; 35: 169-173.
3. TC Sağlık Bakanlığı, Tüberküloz Tanı ve Tedavi Rehberi. Artı6 Medya Tanıtım Matbaa Ltd. Sti. 2. Baskı Ankara; 2019.
4. McNerney R, Maeurer M, Abubakar I, Marais B, McHugh TD et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. Journal of Infectious Disease 2011; 205: 147-158. doi: 10.1093/infdis/ jir860
5. Norbis L, Miotto P, Alagna R, Cirillo DM. Tuberculosis: lights and shadows in the current diagnostic landscape. New Microbiology 2013; 36 (2): 111-120. doi: 10.1186/1758-2652- 13-40
6. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. Nature Reviews Immunology 2011; 11 (5): 343-354. doi: 10.1038/nri2960
7. Wallis RS, Kim P, Cole S, Hanna D, Andrade BB et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infectious Diseases 2013; 13 (4): 362-372. doi: 10.1016/S1473-3099(13)70034-3
8. Wallis RS, Wang C, Doherty TM, Onyebujoh P, Vahedi M et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infectious Diseases 2010; 10 (2): 68-69. doi: 10.1016/ S1473-3099(09)70042-8
9. Miotto P, Mwangoka G, Valente IC, Norbis L, Sotgiu G et al. miRNA signatures in sera of patients with active pulmonarytuberculosis. PLoS One 2013; 8 (11): e80149. doi: 10.1371/journal.pone.0080149
10. Lawn SD, Zumla AI. Tuberculosis. Lancet 2011; 378 (9785): 57-72. doi: https://doi.org/10.1016/S0140-6736(10)62173-3
11. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Reviews 2009; 28: 369-378. doi: 10.1007/s10555-009-9188-5
12. Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 2005; 309 (5740): 1573-1576. doi: 10.1126/science.1115079
13. BACTEC MGIT 960 User’s Manual; 2014.
14. Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes. Approved Standard M24-A2. 2nd ed. Wayne, PA, USA: CLSI; 2011.
15. Kamerbeek J, Schouls L, Kolk A, Agterveld M, Soolingen D et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. Journal of Clinical Microbiolology 1997; 35: 907-914. doi: 10.1128/jcm.35.4.907-914.1997
16. Gagneux, S. Host-pathogen coevolution in human. Philosophical transactions of the Royal Society of London. Series B. Biological sciences 2012; 19, 367 (1590): 850-859. doi: https://doi.org/10.1098/rstb.2011.0316
17. Moller M, Wit E, Hoal, EG. Past present and future directions in human genetic susceptibility to tuberculosis. FEMS Immunology and Medical Microbiology 2010; 58: 3-26. doi: 10.1111/j.1574-695X.2009.00600.x
18. Maartens G, Wilkinson RJ. Tuberculosis. Lancet 2007; 370: 2030-2043. doi: https://doi.org/10.1016/S0140-6736(07)61262- 8
19. Malik ANJ, Godfrey-Faussett P. Effects of genetic variability of Mycobacterium tuberculosis strains on the presentation of disease. Lancet Infectious Diseases 2005; 5: 174-183. doi: 10.1016/S1473-3099(05)01310-1
20. Coscolla M, Gagneux S. Consequences of genomic diversity in Mycobacterium tuberculosis. Seminars in Immunology 2014; 26: 431-444. doi: 10.1016/j.smim.2014.09.012
21. Comas I, Gagneux S. A role for systems epidemiology in tuberculosis research. Trends in Microbiology 2011; 19 (10): 492-500. doi: 10.1016/j.tim.2011.07.002
22. Çavuşoğlu C, Yılmaz FF, Durusoy Onmuş İR, Bozdemir T, Taşlı H, Hoşgör Limoncu M. Genotype distribution of Mycobacterium tuberculosis in the Aegean Region and associated demographic factors. Turkish Journal of Medical Sciences 2017; 47 (5): 1593-1601. doi: 10.3906/sag-1607-115
23. Zhou Y, Xia Z, Cheng Z, Xu G, Yang X et al. Inducible microRNA-590-5p inhibits host antiviral response by targeting the soluble interleukin-6 (IL6) receptor. Journal of Biolological Chemistry 2018; 293 (47): 18168-18179. doi: 10.1074/jbc. RA118.005057
24. Ramirez HA, Pastar I, Jozic I, Stojadinovic O, Stone RC et al. Staphylococcus aureus Triggers Induction of miR-15B5P to Diminish DNA Repair and Deregulate Inflammatory Response in Diabetic Foot Ulcers. The Journal of Investigative Dermatology 2018; 138 (5): 1187-1196. doi: https://doi. org/10.1016/j.jid.2017.11.038
25. Wang C, Yang S, Liu CM, Jiang TT, Chen ZL et al. Screening and identification of four serum miRNAs as novel potential biomarkers for cured pulmonary tuberculosis. Tuberculosis 2018; 108: 26e34. doi: 10.1016/j.tube.2017.08.010
26. Kleinsteuber K, Heesch K, Schattling S, Kohns M, SanderJülch C, Walzl G et al. Decreased expression of miR-21, miR26a, miR-29a, and miR-142-3p in CD4+ T cells and peripheral blood from tuberculosis patients. PLoS One 2013; 8 (4): e61609. doi: 10.1371/journal.pone.0061609. doi: 10.1371/ journal.pone.0061609
27. Zhao Z, Hao J, Li X, Chen Y, Qi X. MiR-21-5p regulates mycobacterial survival and inflammatory responses by targeting Bcl-2 and TLR4 in Mycobacterium tuberculosisinfected macrophages. FEBS Letters 2019; 593: 1326-1335. doi: 10.1002/1873-3468.13438
28. Zhu Y, Zhang S, Li Z, Wang H, Li Z et al. miR-125b-5p and miR-99a-5p downregulate human γδ T-cell activation and cytotoxicity. Cellular and Molecular Immunology 2019; 16: 112-125. doi: 10.1038/cmi.2017.164
29. Portevin D, Gagneux S, Comas I, Young D. Human macrophage responses to clinical isolates from the Mycobacterium tuberculosis complex discriminate between ancient and modern lineages. PLoS Pathogens 2011; 7 (3): e1001307. doi: https://doi.org/10.1371/journal.ppat.1001307
30. Krishnan N, Malaga W, Constant P, Caws M, Thi Hoang Chau T, Salmons J et al. Mycobacterium tuberculosis lineage influences innate immune response and virulence and is associated with distinct cell envelope lipid profiles. PLoS ONE 2011; 6: e23870. doi: https://doi.org/10.1371/journal.pone.0023870
31. Coussens AK, Wilkinson RJ, Nikolayevskyy V, Elkington PT, Hanifa Y, Islam K et al. Ethnic variation in inflammatory profile in tuberculosis. PLoS Pathog. 2013;9(7):e1003468. doi: 10.1371/journal.ppat.1003468
32. Demissie A, Abebe M, Aseffa A, Rook G, Fletcher H et al. Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL4 antagonist IL4δ2. Journal of Immunology 2004; 172: 6938- 6943. doi: 10.4049/jimmunol.172.11.6938
33. Veenstra H, Crous I, Brahmbhatt S, Lukey P, Beyers N et al. Changes in the kinetics of intracellular IFN-γ production in TB patients during treatment. Clinical Immunology 2007; 124: 336-344. doi: 10.1016/j.clim.2007.05.014
34. van Crevel R, Karyadi E, Preyers F, Leenders M, Kullberg BJ et al. Increased production of interleukin 4 by CD4+ and CD8+ T cells from patients with tuberculosis is related to the presence of pulmonary cavities. Journal of Infectious Diseases 2000; 181: 1194-1197. doi: 10.1016/j.clim.2007.05.014
35. Demissie A, Wassie L, Abebe M, Aseffa A, Rook G et al. The 6- kilodalton early secreted antigenic target-responsive, asymptomatic contacts of tuberculosis patients express elevated levels of interleukin-4 and reduced levels of gamma interferon. Infection and Immunity 2006; 74: 2817-2822. doi: 10.1128/IAI.74.5.2817-2822.2006
36. Wassie L, Demissie A, Aseffa A, Abebe M, Yamuah L et al. Ex vivo cytokine mRNA levels correlate with changing clinical status of Ethiopian TB patients and their contacts over time. PLoS ONE 2008; 3 (1): e1522. doi: 10.1371/journal. pone.0001522
37. Djoba Siawaya JF, Ruhwald M, Eugen-Olsen J, Walzl G. Correlates for disease progression and prognosis during concurrent HIV/TB infection. International Journal of Infectious Diseases 2007; 11: 289-299. doi: 10.1016/j. ijid.2007.02.001